Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | T319A |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FGFR1 T319A lies within Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). T319A results in decreased proliferation relative to wild-type Fgfr1 in a competition assay and decreased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a loss of Fgfr1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 inact mut FGFR1 T319A |
Transcript | NM_023110.3 |
gDNA | chr8:g.38421923T>C |
cDNA | c.955A>G |
Protein | p.T319A |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001174063.2 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
NM_023110.2 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_047421570.1 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_017013222.2 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
NM_001174063.1 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_017013221.2 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38421923T>C | c.955A>G | p.T319A | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 T319A | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 T319A | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 T319A | Advanced Solid Tumor | predicted - resistant | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with E7090 in culture (PMID: 34272467). | 34272467 |
FGFR1 T319A | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 T319A | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 T319A | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |